Nevirapine
Drug · tier A · 8 trials (0 recruiting) · 17 publications · score 80.0
Doravirine
Drug · tier A · 8 trials (1 recruiting) · 10 publications · score 79.5
Etravirine
Drug · tier A · 8 trials (0 recruiting) · 16 publications · score 79.5
Emtricitabine
Drug · tier A · 8 trials (0 recruiting) · 13 publications · score 79.0
Lopinavir
Drug · tier A · 8 trials (0 recruiting) · 16 publications · score 79.0
Elvitegravir
Drug · tier A · 8 trials (0 recruiting) · 17 publications · score 78.5
Efavirenz
Drug · tier A · 8 trials (0 recruiting) · 13 publications · score 77.0
Enfuvirtide
Biologic · tier A · 8 trials (0 recruiting) · 10 publications · score 77.0
Tipranavir
Drug · tier A · 8 trials (0 recruiting) · 11 publications · score 77.0
Cabotegravir
Drug · tier A · 8 trials (0 recruiting) · 16 publications · score 76.0
Lamivudine
Drug · tier A · 8 trials (0 recruiting) · 14 publications · score 76.0
Saquinavir
Drug · tier A · 8 trials (0 recruiting) · 15 publications · score 76.0
Amprenavir
Drug · tier A · 8 trials (0 recruiting) · 11 publications · score 75.0
Rifabutin
Drug · tier A · 8 trials (0 recruiting) · 14 publications · score 75.0
Ritonavir
Drug · tier A · 8 trials (0 recruiting) · 15 publications · score 74.0
Tenofovir Disoproxil Fumarate
Drug · tier A · 8 trials (1 recruiting) · 16 publications · score 73.5
Zidovudine
Drug · tier A · 8 trials (0 recruiting) · 15 publications · score 73.5
Maraviroc
Drug · tier A · 8 trials (0 recruiting) · 14 publications · score 73.0
Ibalizumab
Biologic · tier A · 8 trials (0 recruiting) · 7 publications · score 63.5
Nicotine
Drug · tier A · 8 trials (1 recruiting) · 7 publications · score 62.0
Fosamprenavir Calcium
Drug · tier A · 8 trials (0 recruiting) · 0 publications · score 50.0
Atazanavir Sulfate
Drug · tier A · 8 trials (0 recruiting) · 0 publications · score 48.5
Abacavir Sulfate
Drug · tier A · 8 trials (0 recruiting) · 2 publications · score 47.5
Somatropin
Biologic · tier A · 8 trials (0 recruiting) · 0 publications · score 46.5
Raltegravir Potassium
Drug · tier A · 8 trials (0 recruiting) · 0 publications · score 43.5
Research map, not treatment advice. Built 2026-10-07.